Riskpilot← Back to searchSign inGet full accessKiadis Pharma Sweden AB
ABIn liquidationOrg 5591994289Economic activity was not specified by tax authority · NACE 0000Est. 20191 employees
Revenue 2021
SEK 0
EBITDA margin
—
-43% vs 2019
Equity ratio
95.9%
Financial strength
Net profit 2021
SEK 3K
-83% vs 2019
| Revenue | SEK 0 | — |
| EBITDA | SEK 13K | -43% |
| Net profit | SEK 3K | -83% |
| Total assets | SEK 74K | -78% |
| Equity | SEK 71K | +4% |
| Employees | 1 | — |
Legal name
Kiadis Pharma Sweden AB
Org number
5591994289
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
20 mars 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2021-06-30
Financial year
January – December
Company purpose
Bolaget ska utveckla och marknadsföra nya läkemedel med ett primärt men inte enbart fokus på onkologi och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2021 |
|---|---|---|
| Revenue | 482 | 0 |
| Staff expenses | — | — |
| EBITDA | 23 | 13 |
| Depreciation & amort. | −0 | −0 |
| EBIT | 23 | 13 |
| Net financials | — | −7 |
| Profit before tax | 23 | 6 |
| Tax | −5 | −3 |
| Net profit | 18 | 3 |
| Item | 2019 | 2021 |
|---|---|---|
| Total assets | 333 | 74 |
| Equity | 68 | 71 |
| Long-term debt | 0 | 0 |
| Short-term debt | 265 | 3 |
| Total debt | 265 | 3 |
EBITDA margin
1300000.0%
This company
15.8%
Market median
+8227748% vs market
20192021
Equity ratio
95.9%
This company
38.2%
Market median
+151% vs market
20192021
Return on equity
4.2%
This company
18.4%
Market median
-77% vs market
20192021
Net profit margin
300000.0%
This company
8.1%
Market median
+3703604% vs market
20192021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192021
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20192021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-01-01 – 2021-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-03-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LG External Signatory | External Signatory | 2020 |
BJ Liquidator | Liquidator | 2020 |
| Former (2) | ||
AK External Signatory | External Signatory | 2020 – 2021 |
AI Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2020 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2021 | |
| Board of Directors | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Kiadis Pharma Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Gustav Andersson | External Signatory | 0 companies |
| Bengt Junior Niklas Nygårds | Liquidator | 0 companies |
| Arthur Karel Lahr | External Signatory | 0 companies |
| Annika Isabel Saavedra Oxelgren | Authorized Recipient of Service | 0 companies |
| Inger Margareta Dahle | Deputy Board Member | 0 companies |
| Margaretha Elisabeth Awuraama Hoppe | Deputy Board Member | 0 companies |
| Ulrika Margareta Ahlholm | Board of Directors | 0 companies |
| Paulus Cornelis van Hagen | Board of Directors | 0 companies |